Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.59 |
| ▸ | GSK3B | P49841 | 7/20 | 0.46 |
| ▸ | PIM1 | P11309 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1957355 | 0.92 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3CAPIK3CBGSK3B | |
| SCHEMBL1959680 | 0.89 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3CAPIK3CBGSK3B | |
| SCHEMBL456804 | 0.88 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3CAPIK3CBGSK3B | |
| SCHEMBL2056099 | 0.88 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CAPIK3CBGSK3B | |
| SCHEMBL1772173 | 0.85 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3CAPIK3CBGSK3B | |
| SCHEMBL457717 | 0.85 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CAPIK3CBGSK3B | |
| SCHEMBL1959511 | 0.85 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CAPIK3CBGSK3B | |
| SCHEMBL459145 | 0.84 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3CAPIK3CBGSK3B | |
| SCHEMBL1772066 | 0.84 | PIK3CD (0.67) | PIK3CDPIK3CGPIK3CAPIK3CBGSK3B | |
| SCHEMBL1957720 | 0.84 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3CAPIK3CBGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507231-A1 | INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | claimed |
| WO-2011067366-A1 | INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | claimed |
| EP-2507231-A1 | INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | disclosed |
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| WO-2011067366-A1 | INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | PI4KA, PIP4K2B, PI4KB | PIK3CD 11/4885PIK3CG 15/4885PIK3CA 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.